Boardroom Alpha
Boardroom Alpha
NATR · Current Report (Form 8-K) · Filed May 11, 2026

Natures Sunshine Products Inc — Current Report (Form 8-K)

Form
8-K
Filed
May 11, 2026
Period
May 11, 2026
Ticker
NATR
Accession
0001628280-26-033161
Boardroom Alpha · Filing insights

Nature’s Sunshine CFO L. Shane Jones resigns, effective June 5, 2026; Jonathan Lanoy named interim Principal Financial Officer.

About Natures Sunshine Products Inc
Market cap
$367M
1Y TSR
+56.1%
3Y TSR
+22.0%
Board grade
A-
Sector
Consumer Defensive
CEO
Kenneth G Romanzi
Last annual meeting: May 6, 2026 · View full Natures Sunshine Products Inc profile →
natr-20260511

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 11, 2026

 NS-logo-darkgreen.jpg
NATURE’S SUNSHINE PRODUCTS, INC.
(Exact name of registrant specified in its charter)
 
Utah 001-34483 87-0327982
(State or other jurisdiction of
incorporation)
 (Commission File Number) (I.R.S. Employer Identification No.)
 2901 West Bluegrass Blvd., Suite 100
Lehi, Utah 84043
(Address of principal executive offices and zip code)

Registrant’s telephone, including area code:  (801) 341-7900

N/A
(Former name and former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of each ClassTrading SymbolName of each exchange on which registered
Common Stock, no par valueNATRNasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§203.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Chief Financial Officer

On May 8, 2026, L. Shane Jones notified Nature’s Sunshine Products, Inc. (the “Company”) that he is resigning as the Company’s Chief Financial Officer effective June 5, 2026. As the Company’s Chief Financial Officer, Mr. Jones also served as the Company’s Principal Financial Officer. Mr. Jones’ resignation was not the result of any disagreement with the Company on any matter relating to the Company’s financial reporting or accounting policies, procedures, estimates, or judgments.

Appointment of Principal Financial Officer

On May 8, 2026, Mr. Jonathan D. Lanoy was appointed to serve as the Company’s Interim Principal Financial Officer. Mr. Lanoy, 51, currently serves as the Company’s Senior Vice President, Chief Accounting Officer, and Principal Accounting Officer, positions in which he has served since January 24, 2023. Prior to that he served as the Company’s Vice President of Finance and Corporate Controller since February 2017, and in various other positions in the finance department of the Company since 2008. Before joining the Company, Mr. Lanoy was an assurance manager at the public accounting firm of Ernst & Young. Mr. Lanoy is a Certified Public Accountant and holds a Masters of Professional Accountancy and a Bachelor of Arts degree in Accounting from Weber State University.

Mr. Lanoy and the Company previously entered into an employment agreement (the “Employment Agreement”) pursuant to which Mr. Lanoy will receive an annual base salary of $301,551 and have a target annual bonus percentage of 50 percent of his base salary. The Employment Agreement also provides that Mr. Lanoy will receive the following benefits if his employment is terminated by the Company without Cause, if he resigns with Good Reason, or if his employment is terminated as a result of his death or Incapacity:

payment of all accrued and unpaid base salary through the date of his termination and reimbursement of any unreimbursed expenses (“Accrued Pay”);
monthly severance payments equal to one-twelfth of his annual base salary for a period of 12 months; and
reimbursement for the costs he incurs for continuation of his health insurance coverage under COBRA for a period of 12 months.

The terms Cause, Good Reason and Incapacity are defined in the Employment Agreement. The severance benefits described above, other than the Accrued Pay, are subject to Mr. Lanoy executing a release in favor of the Company and complying with the restrictive covenants set forth in the Employment Agreement, including a covenant not to compete with the Company for a period of 12 months following the termination of his employment with the Company.

The description of the terms and provisions of the Employment Agreement set forth above is qualified in its entirety by reference to the actual Employment Agreement, a copy of which is attached hereto as Exhibit 10.1, and incorporated herein by reference.

There is no arrangement or understanding between Mr. Lanoy and any other person pursuant to which he was selected as an officer of the Company. Mr. Lanoy has no family relationship (within the meaning of Item 401(d) of Regulation S-K) with any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer. There has been no transaction since the beginning of the Company’s last fiscal year, and there is no currently proposed transaction, in excess of $120,000 in which the Company is or was a participant and in which Mr. Lanoy or any of his immediate family members (within the meaning of Item 404 of Regulation S-K) had or will have a direct or indirect material interest.





Item 9.01    Financial Statements and Exhibits
Item No. Exhibit
10.1


104Cover Page Interactive Data File (embedded within the Inline XBRL document)




SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 NATURE’S SUNSHINE PRODUCTS, INC.
   
Dated: May 11, 2026By:/s/ Nathan G. Brower
  Nathan G. Brower, Executive Vice President, General Counsel and Corporate Secretary

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Natures Sunshine Products Inc (NATR)

Reference

Frequently asked questions

When did Natures Sunshine Products Inc file this 8-K?
Natures Sunshine Products Inc (NATR) filed this Current Report (Form 8-K) with the SEC on May 11, 2026. The accession number assigned by EDGAR is 0001628280-26-033161.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Nature’s Sunshine CFO L. Shane Jones resigns, effective June 5, 2026; Jonathan Lanoy named interim Principal Financial Officer. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Natures Sunshine Products Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Natures Sunshine Products Inc has filed under CIK 275053, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer